TP53 and neoplasm: Emerging evidence shows that alterations in the TP53 pathway have a substantial role in modulating immune checkpoint activity, thus shaping the tumour microenvironment and thereby inducing cancer immune evasion and treatment responses and indicating the potential for combined therapeutic strategies [16,17,18].